Medically reviewed by Susan Bard, MD Atopic dermatitis (AD), a common form of eczema, is a chronic (long-term) skin condition ...

Pregnant patients with T2IDs using dupilumab did not have an increased rate of adverse events when compared with patients not receiving dupilumab.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Galderma Group AG reported robust financial results for Q1 2025, with net sales reaching a record $1.129 billion, marking an 8.3% year-on-year growth at constant currency. The company’s stock ...

eosinophilic esophagitis and prurigo nodularis. However, customary dynamics of the annual reset of insurance plans in the first quarter hurt sales slightly. Dupixent sales rose 23.5% in Europe and ...

The drug is approved for prurigo nodularis and atopic dermatitis. RBC described the launch as ahead of expectations and noted strong early uptake across both indications. Jefferies emphasized ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion, while the ...

Barzolvolimab's Phase 3 trials target chronic spontaneous urticaria, chronic inducible urticaria, eosinophilic esophagitis, prurigo nodularis, and atopic dermatitis, with mixed competitive prospects.

The FDA approved Nemluvio for use in patients with moderate to severe atopic dermatitis in December, following an initial approval in prurigo nodularis in August. Galderma is now facing off ...

to treat adults with prurigo nodularis. It is not known if NEMLUVIO is safe and effective in children with prurigo nodularis under 18 years of age. Do not take NEMLUVIO if you are allergic to ...